RESILIENT

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy
Contact phone
Clinical Trials Office – 517-364-9402
Principal investigator
Gordan Srkalovic, M.D., PhD
Trial Category
Cancer
Trial SubCategory
Lung